Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Hyaluronates Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 4664-D

    Medicare Part B Step Therapy Hyaluronates

    Customize your policy alerts

    Sign up for zing_health Policy 4664-D alerts

    Get alerted when Policy 4664-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage of preferred and non-preferred hyaluronate products for Medicare Part B members receiving FDA-approved osteoarthritis treatment; non-preferred products require prior authorization and a qualifying clinical exception.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Hyaluronates
    Policy CodePolicy 4664-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a prior authorization exception review for non-preferred hyaluronate products and document prior use within 365 days or intolerance to both required preferred products.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Preferred osteoarthritis-multi products
    9Non-preferred osteoarthritis-multi products
    3Non-preferred osteoarthritis-single products
    365 daysPrior-treatment lookback

    Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Osteoarthritis-multi non-preferred coverage

    Coverage for a non-preferred osteoarthritis-multi product is provided when either of the following criteria is met:

    Qualifying exception for osteoarthritis-multi

    • Recent treatment with requested product: The member has received treatment with the requested non-preferred product in the past 365 days.Past 365 days
    • Intolerance to preferred products: The member has a documented intolerable adverse event to both preferred products, Euflexxa and Synvisc.Both preferred products

    Osteoarthritis-single non-preferred coverage

    Coverage for a non-preferred osteoarthritis-single product is provided when either of the following criteria is met:

    Qualifying exception for osteoarthritis-single

    • Recent treatment with requested product: The member has received treatment with the requested non-preferred product in the past 365 days.Past 365 days
    • Intolerance to preferred products: The member has a documented intolerable adverse event to both preferred products, Durolane and Synvisc-One.Both preferred products

    The step therapy program applies only when the requested treatment is for an indication that is FDA-approved for the preferred product.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required for Non-Preferred Products

    Prior authorization is required for coverage of non-preferred hyaluronate products. The review evaluates clinical circumstances that exclude use of preferred products and may consider prior treatment with the requested product; preferred products may also require clinical prior authorization review.

    • Program applies to Medicare Part B hyaluronate products and members new to treatment with the non-preferred product.
    • Step therapy applies in addition to applicable NCD, LCD, and Medicare Part B utilization-management requirements.
    • Osteoarthritis-Multi non-preferred products: Gelsyn-3, GenVisc 850, Hyalgan, Hymovis, Orthovisc, Supartz FX, Triluron, Trivisc, and Visco-3.
    • Osteoarthritis-Single non-preferred products: Synvisc-One, Gel-One, and Monovisc.
    Step Therapy

    Osteoarthritis-Multi Exception

    A non-preferred Osteoarthritis-Multi product may be approved when either qualifying exception pathway is met.

    • The member received treatment with the requested non-preferred product within the past 365 days.
    • The member has a documented intolerable adverse event to both preferred products: Euflexxa and Synvisc.
    Step Therapy

    Osteoarthritis-Single Exception

    A non-preferred Osteoarthritis-Single product may be approved when either qualifying exception pathway is met.

    • The member received treatment with the requested non-preferred product within the past 365 days.
    • The member has a documented intolerable adverse event to both preferred products: Durolane and Synvisc-One.

    Unsupported block type: documentation_variant

    Denial Risk

    No Qualifying Step-Therapy Exception

    Coverage is not approved when the requested treatment is not for an FDA-approved indication for the preferred product, or when the applicable exception criteria and supporting documentation are not met.

    • The program applies to members requesting treatment for an indication that is FDA-approved for the preferred product.
    • Absent qualifying prior use within the past 365 days or documented intolerable adverse events to both applicable preferred products, the non-preferred product does not meet the step-therapy exception requirements.
    • Applicable NCD, LCD, and Medicare Part B utilization-management requirements still apply.

    Policy Background

    Hyaluronate products are used as intra-articular viscosupplementation therapies for osteoarthritis. Under this Medicare Part B policy, step therapy applies to requests for FDA-approved osteoarthritis indications; non-preferred products may qualify through an exception pathway based on recent prior use or documented intolerance to the required preferred products.

    Initial Therapy Criteria

    Osteoarthritis-multi initial therapy

    For initial requests for non-preferred osteoarthritis-multi hyaluronate products, coverage is available when either qualifying exception is met:

    Osteoarthritis-multi initial exception

    • Recent treatment with requested product: The member has received the requested non-preferred product in the past 365 days.Past 365 days
    • Intolerance to preferred products: The member has a documented intolerable adverse event to both preferred products, Euflexxa and Synvisc.Both preferred products

    Osteoarthritis-single initial therapy

    For initial requests for non-preferred osteoarthritis-single hyaluronate products, coverage is available when either qualifying exception is met:

    Osteoarthritis-single initial exception

    • Recent treatment with requested product: The member has received the requested non-preferred product in the past 365 days.Past 365 days
    • Intolerance to preferred products: The member has a documented intolerable adverse event to both preferred products, Durolane and Synvisc-One.Both preferred products

    Preferred Product Step Therapy

    StepPreferred productsRequired documentation or useCoverage outcome
    1Euflexxa and SynviscUse the requested non-preferred product within the past 365 days, or document an intolerable adverse event to both preferred products.Covered when either exception is met.
    StepPreferred productsRequired documentation or useCoverage outcome
    1Durolane and Synvisc-OneUse the requested non-preferred product within the past 365 days, or document an intolerable adverse event to both preferred products.Covered when either exception is met.
    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Hyaluronates
    Policy CodePolicy 4664-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a prior authorization exception review for non-preferred hyaluronate products and document prior use within 365 days or intolerance to both required preferred products.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Documentation RequirementsPolicy BackgroundInitial Therapy CriteriaPreferred Product Step Therapy